All news
Europe’s Beating Cancer Plan: The Real Failure Is Implementation
29 April 2026On 14 April 2026, MEP Vlad Voiculescu (Renew, Romania) presented his report on the implementation of Europe’s Beating Cancer Plan in the European...
Start Moving, Stay Moving: Your Path to the Fun Run 2026
28 April 2026Two practical webinars from DiCE and OAC break down the barriers to movement, showing how to start, stay motivated, and build sustainable habits. W...
Switching Off KRAS: A Promising Breakthrough in Pancreatic Cancer Treatment
28 April 2026Results from the RASolute 302 phase 3 trial show the targeted drug Daraxonrasib improves survival in metastatic pancreatic cancer after prior treat...
Landmark New England Journal of Medicine (NEJM) Publication Advances Gastric Cancer Prevention
28 April 2026A new New England Journal of Medicine paper, led by International Agency for Research on Cancer, outlines practical guidance for Helicobacter pylor...
Unblocking Multinational Clinical Trials in Europe: Progress, but More to Do
18 April 2026New Clinical Trials Regulation guidance from the European Commission introduces an Article 11 workaround to ease trial delays. While improving mult...
When a Parent Has Cancer: How to Talk to Your Children, Honestly and Gently
16 April 2026Telling a child you have cancer is never easy. This practical guide helps families navigate the conversation with honesty, reassurance, and care—...
Investing in Impact: DiCE Supports Member Organisations through ECCAM Grants
27 March 2026This spring, DiCE dedicated its first 2026 grant round to ECCAM, supporting 11 Member Organisations with funding between €1,000 and €1,500. A s...
Patents, Prices, and Patients: a Global Campaign Putting Access to Medicines Under the Spotlight
27 March 2026New global campaign Patients and Patents highlights how pharmaceutical patent practices affect access to affordable medicines. With clear tools and...
A Turning Point Before Surgery: CASSANDRA Redefines Neoadjuvant Therapy in Pancreatic Cancer
26 March 2026The CASSANDRA phase III trial shows that the PAXG regimen significantly improves outcomes over mFOLFIRINOX in resectable pancreatic cancer. This pa...
Europe Approves First-line Immunotherapy for Advanced Anal Cancer
26 March 2026New progress for advanced anal cancer in Europe. The European Commission has approved retifanlimab with chemotherapy as a first-line treatment, hel...